Sugi Predict

Sugi Predict / Compounds / SCHEMBL1323767

SCHEMBL1323767

SCHEMBL1323767

COc1cc2nccc(Cl)c2cc1C(N)=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 6/20 0.56
▸ AURKB Q96GD4 3/20 0.56
▸ AURKA O14965 2/20 0.56
▸ MET P08581 2/20 0.56
▸ TEK Q02763 2/20 0.56
▸ PDGFRB P09619 3/20 0.53
▸ PDGFRA P16234 3/20 0.53
▸ RET P07949 2/20 0.53
▸ KIT P10721 2/20 0.53
▸ FGFR1 P11362 2/20 0.53
▸ FLT1 P17948 2/20 0.53
▸ FLT4 P35916 2/20 0.53
▸ ABL1 P00519 2/20 0.53
▸ RIPK2 O43353 1/20 0.53
▸ ERN1 O75460 1/20 0.53
▸ STK10 O94804 1/20 0.53
▸ MAP3K6 O95382 1/20 0.53
▸ ESR1 P03372 1/20 0.53
▸ ADORA3 P0DMS8 1/20 0.53
▸ BCR P11274 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31218187 1.00 KDR (0.56) KDRAURKBAURKAMETTEK
SCHEMBL6004853 0.94 IRAK4 (0.53) KDRAURKBAURKAMETTEK
Methylamine SCHEMBL22505658 0.88 AXL (0.49) KDRAURKBAURKAMETTEK
SCHEMBL1132245 0.87 AXL (0.51) METEGFRKDM4E
SCHEMBL1891155 0.87 SRC (0.44) KDRAURKBAURKAMETTEK
SCHEMBL27104752 0.86 IRAK4 (0.51) KDRAURKBAURKAMETTEK
SCHEMBL1132184 0.86 GAA (0.51) KDRAURKBMETPDGFRBPDGFRA
Hydrochloric Acid SCHEMBL7235016 0.86 AXL (0.50) KDRAURKBAURKAMETTEK
SCHEMBL22505587 0.86 AXL (0.53) KDRAURKBAURKAMETTEK
Hydrochloric Acid SCHEMBL1892857 0.85 GAA (0.50) KDRAURKBMETPDGFRBPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 281 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112654603-B Preparation method of lenvatinib 意迪那有限公司 2024-05-03 — — CN claimed
CN-117865887-A Preparation method of lenvatinib mesylate intermediate 山东鲁抗医药股份有限公司 2024-04-12 — — CN claimed
CN-116874420-B Preparation method of lenvatinib intermediate 4-chloro-7-methoxyquinoline-6-amide 山东轩德医药科技有限公司 2024-03-26 — — CN claimed
CN-115466211-B N-phenylquinoline-4-amine compound and application thereof 中国人民解放军空军军医大学 2024-02-23 — — CN claimed
CN-116874420-A Preparation method of lenvatinib intermediate 4-chloro-7-methoxyquinoline-6-amide 山东轩德医药科技有限公司 2023-10-13 — — CN claimed
CN-115322149-A Alvatinib mesylate impurity and preparation method thereof 思科(深圳)药物研发有限公司 2022-11-11 — — CN claimed
CN-115166064-A Separation detection method for fluvastatin impurities 重庆医药工业研究院有限责任公司 2022-10-11 — — CN claimed
CN-112110856-B Preparation method of 4-chloro-7-methoxyquinoline-6-amide 南京法恩化学有限公司 2022-09-06 — — CN claimed
CN-113831282-A Novel ranvatinib derivative, preparation method and application thereof 北京四环制药有限公司 2021-12-24 — — CN claimed
CN-113307767-A Synthetic method of lenvatinib 山东汇海医药化工有限公司 2021-08-27 — — CN claimed
US-20210188778-A1 NOVEL POLYMORPHS OF 4-[3-CHLORO-4-(N'-CYCLOPROPYL UREIDO)PHENOXY]-7-METHOXYQUINOLINE-6-CARBOXAMIDE, ITS SALTS AND PROCESS FOR THE PREPARATION THEREOF MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) 2021-06-24 — — US claimed
CN-112110856-A Preparation method of 4-chloro-7-methoxyquinoline-6-amide 南京法恩化学有限公司 2020-12-22 — — CN claimed
CN-111377865-A Preparation method of high-purity lenvatinib 北京启慧生物医药有限公司 2020-07-07 — — CN claimed
CN-111349045-A Synthetic method of lenvatinib and novel intermediate 江苏万邦生化医药集团有限责任公司 2020-06-30 — — CN claimed
WO-2019111283-A1 NOVEL POLYMORPHS OF 4-[3-CHLORO-4-(N'-CYCLOPROPYL UREIDO)PHENOXY]-7-METHOXYQUINOLINE-6-CARBOXAMIDE, ITS SALTS AND PROCESS FOR THE PREPARATION THEREOF MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) 2019-06-13 — — WO claimed
CN-105801481-A Lenvatinib synthesizing method 湖南欧亚生物有限公司 2016-07-27 — — CN claimed
US-20070117842-A1 Polymorph of 4-[3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6- quinolinecarboxamide and a process for the preparation of the same EISAI R&D MANAGEMENT CO., LTD. (JP) 2007-05-24 — — US claimed
CN-116239531-B Levalatide preparation method of nylon 山东新时代药业有限公司 2025-11-25 — — CN disclosed
EP-1415987-A1 NITROGENOUS AROMATIC RING COMPOUNDS Eisai Co., Ltd. (JP) 2004-05-06 — — EP disclosed
US-20040053908-A1 Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-03-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053908-A1 Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective VEGFA, UACA, UTS2R KDR 22/4885AURKB 2738/4885AURKA 2691/4885
US-20070117842-A1 Polymorph of 4-[3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6- quinolinecarboxamide and a process for the preparation of the same CYP3A4, CYP3A7, CYP2D6 KDR 2743/4885AURKB 2432/4885AURKA 872/4885
US-20210188778-A1 NOVEL POLYMORPHS OF 4-[3-CHLORO-4-(N'-CYCLOPROPYL UREIDO)PHENOXY]-7-METHOXYQUINOLINE-6-CARBOXAMIDE, ITS SALTS AND PROCESS FOR THE PREPARATION THEREOF CYP4B1, UGT1A1, CYP3A4 KDR 4133/4885AURKB 3755/4885AURKA 2285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.